AVEO Pharmaceuticals
AVEO Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at AVEO Pharmaceuticals.
AVEO Pharmaceuticals is a company.
Key people at AVEO Pharmaceuticals.
Key people at AVEO Pharmaceuticals.
AVEO Oncology (formerly AVEO Pharmaceuticals, Inc.) is an oncology-focused biopharmaceutical company that develops and commercializes targeted cancer therapies, primarily serving patients with advanced renal cell carcinoma (RCC) and other unmet needs in oncology.[3][4][5] It markets FOTIVDA (tivozanib), an approved VEGF tyrosine kinase inhibitor for relapsed or refractory advanced RCC after two or more prior therapies, while advancing investigational programs like ficlatuzumab for head and neck cancer and AV-380 for cancer cachexia.[5][7] As a wholly owned subsidiary of LG Chem since January 2023, AVEO leverages global resources to expand its portfolio, addressing treatment gaps through effective, tolerable therapies that enable patients to maintain daily life.[3][5]
A separate entity, Aveo Pharmaceuticals Limited (India-based), manufactures generic pharmaceutical formulations including tablets, capsules, ointments, and oncology products for domestic and export markets, prioritizing affordable, GMP-compliant drugs.[1][2] Given the query's focus and AVEO's prominence in oncology innovation, this overview centers on AVEO Oncology, a portfolio-style biotech with strong growth via LG Chem integration and active clinical advancements.[5][8]
AVEO Pharmaceuticals originated as a U.S.-based biotech firm, evolving into AVEO Oncology with a focus on oncology drug development; it became a wholly owned subsidiary of LG Chem Life Sciences on January 19, 2023, enhancing its global commercialization capabilities.[3][5][8] Key milestones include U.S. approval and launch of FOTIVDA in 2021 for advanced RCC, building on prior partnerships and a track record in targeted therapies like tivozanib (originally partnered with others before LG Chem).[5][7] The leadership comprises experienced oncology experts, supported by a Scientific Advisory Committee of top specialists guiding clinical and business strategies.[3]
Pivotal moments include LG Chem's acquisition, which unified AVEO's pipeline—including ficlatuzumab (Phase 3 in head and neck cancer) and AV-380 (Phase 1b in cachexia)—with LG Chem's life sciences expertise in oncology and beyond.[5][7] This followed years of development in high-need areas, with recent activity like ASCO 2025 poster presentations signaling ongoing momentum.[5] (Note: The Indian Aveo Pharmaceuticals, founded 2015, started with local formulations and expanded to exports and specialized facilities, but lacks direct ties to the U.S. oncology entity.[1][2])
AVEO Oncology rides the precision oncology wave, targeting VEGF pathways, immunotherapy combinations, and supportive care like cachexia amid rising RCC incidence and demand for tolerable post-immunotherapy options.[5][7] Timing aligns with post-2023 acquisition synergies from LG Chem, accelerating global access as immuno-oncology evolves and combination therapies gain traction—e.g., FOTIVDA in novel RCC combos.[3][5] Market forces favoring AVEO include aging populations driving cancer prevalence, regulatory nods for late-line therapies, and biotech consolidation enabling resource-strapped innovators to scale.[5] It influences the ecosystem by advancing cachexia and head/neck cancer programs, potentially setting standards for symptom management and filling gaps left by broad-spectrum treatments.[7]
AVEO's trajectory points to portfolio expansion and global launches, with FOTIVDA combos in RCC, ficlatuzumab Phase 3 readouts, and AV-380 cachexia data at milestones like ASCO 2025 shaping near-term catalysts.[5][7] Trends like AI-driven oncology, immunotherapy synergies, and supportive care integration will propel growth, amplified by LG Chem's infrastructure for emerging markets. Influence may evolve from U.S.-focused niche player to global leader, prioritizing patient quality-of-life innovations—echoing its core mission to deliver effective cancer care that sustains life.[3][4]
